STRUCTURAL INTERVENTIONS

AMPLATZER™ SEPTAL OCCLUDER

The primary treatment option for atrial septal defects (ASD) is percutaneous, transcatheter closure, and Abbott’s Amplatzer™ Septal Occluder is the proven standard of care1,2—with more than 20 years of global clinical experience in ASD closure.3

FROM THE #1 COMPANY IN CONGENITAL OCCLUDERS3

The Amplatzer™ line not only pioneered structural heart defect occluder devices, it remains the leader in innovation and treatment worldwide. The Amplatzer Septal Occluder offers exceptional safety data, which is significant given that it is the most studied transcatheter ASD closure device on the market.6

The importance of treating patients with Atrial Septal Defects

Patients diagnosed with an ASD, who are indicated for closure with an Amplatzer™ Septal Occluder, exhibit both4:

  • Echocardiographic evidence of ostium secundum ASD
  • Clinical evidence of right ventricular (RV) volume overload (i.e., ratio of pulmonary to systemic flow > 1.5 or RV enlargement)

After receiving ASD closure with the Amplatzer Septal Occluder, Bao remarks:

“I feel better. And maybe (now) I can have more energy to play with my daughter.”

This testimonial relates an account of an individual’s response to the treatment. This patient’s account is genuine, typical and documented. However, it does not provide any indication, guide, warranty or guarantee as to the response other persons may have to the treatment. Responses to the treatment discussed can and do vary and are specific to the individual patient.

Patient Experience after Atrial Septal Defect Occlusion

Patients typically report symptom improvement after the closure of the ASD. In young children, growth rate can increase, and in children and young adults, LV filling improves. When younger patients are treated—those who have less chamber enlargement before repair—there is greater likelihood of normalization of RV size.6
 

Two Amplatzer™ ASD Closure Devices for Optimizing
Patient Care

Abbott offers two devices for percutaneous, transcatheter ASD closure.

Amplatzer™ Septal Occluder

The Amplatzer™ Septal Occluder, approved in the U.S. since 2001, is intended for patients with an ASD in the secundum position or patients who have undergone a fenestrated Fontan procedure and who now require closure of the fenestration.4

The Amplatzer Septal Occluder is designed for ASD closure:

  • Shaped-memory nitinol mesh that securely apposes both sides of the septal wall
  • A wide waist that centers the device and fills the ASD 
  • Polyester material that promotes occlusion and tissue in-growth
  • Can be recaptured and redeployed for precise placement4

The Amplatzer Septal Occluder has the widest range of device sizes, from 4mm to 38mm, enabling the treatment of the widest range of ASD defects.

Amplatzer™ Cribriform Multi-Fenestrated Septal Occluder

The Amplatzer™ Cribriform Occluder is a percutaneous, transcatheter, ASD device intended for the closure of multifenestrated (cribriform) ASDs.7 Multiple, or fenestrated, ASDs that require closure are not uncommon. In fact, nearly 10% of patients with secundum-type ASD are found to have multifenestrated ASDs.5

In many ways similar to the Amplatzer Septal Occluder, the Amplatzer Cribriform design features include: 

  • Self-expanding, double-disc device designed for closure of multi-fenestrated ASDs
  • Matched disc diameters that maximize coverage of multiple fenestrations
  • Ability to be easily recaptured and redeployed for optimal placement3

The Amplatzer Cribriform Occluder disc diameters range from 18 mm to 35 mm.

NEW VERSION AVAILABLE
GET THE AMPLATZER PORTFOLIO APP

The Amplatzer Portfolio App helps physicians determine which Amplatzer Structural Interventions device to use by suggesting applicable devices based on respective Instructions for Use.

MAT-2008368 v2.0 | Item approved for Global OUS use only.

Copyright © 2022 Abbott, 3200 Lakeside Dr, Santa Clara, 95054, U.S.A.
Caution: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or at eifu.abbottvascular.com or at medical.abbott/manuals for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.
Illustrations are artist’s representations only and should not be considered as engineering drawings or photographs. Photos on file at Abbott.
Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

MAT-2000631 v8.0 | Item approved for Global OUS use only.

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of the product that are not approved in other countries or regions.

YOU ARE ABOUT TO LEAVE
www.structural­heart.abbott

You are now leaving www.structuralheart.abbott. Abbott is not responsible for any content published on the third-party website you are about to enter. Abbott has not reviewed and does not endorse any information presented on third-party websites.